Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

First Drug for Frequent Nighttime Urination Approved By FDA

XTALKS VITALS NEWS

Night

Nocturnal polyuria is caused by an overproduction of urine in the evening, which causes patients to wake two or more times per night.

Share this!

March 10, 2017 | by Sarah Hand, M.Sc.

Serenity Pharmaceuticals’ nasal spray, Noctiva, has been approved by the US Food and Drug Administration (FDA) to treat patients who experience frequent nighttime urination. The drug is the first FDA-approved treatment for the condition, known as nocturnal polyuria.

“Today’s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate,” said Dr. Hylton V. Joffe, director of the Division of Bone, Reproductive, and Urologic Products in the FDA’s Center for Drug Evaluation and Research. “It is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.”

Nocturnal polyuria is caused by an overproduction of urine in the evening, which causes patients to wake two or more times per night. Nocturia – the need to urinate multiple times through the night – can be caused by a number of other conditions aside from nocturnal polyuria, including congestive heart failure, diabetes and prostate disease.



According to Serenity Pharmaceuticals, 80 percent of patients who experience nocturia show overproduction of urine during the night associated with nocturnal polyuria. The condition is most common in people over the age of 50, and is estimated to affect tens of millions of adults.

Noctiva works by temporarily reducing urine production, thereby providing more uninterrupted sleep. Administered at night through a nasal spray, the drug is a vasopressin analog – or antidiuretic hormone – which causes the body to retain water.

Noctiva was approved based on the results of two placebo-controlled studies involving 1,045 patients. The average number of nighttime urinations in patients taking Noctiva was modestly reduced, compared to the placebo group.

The most positive outcome of these clinical trials was Noctiva’s ability to reduce most patients’ number of nighttime urinations by 50 percent. Patients taking the drug also showed an increase in the number of nights with one or fewer urinations.

The FDA’s approval of Noctiva does come with a caveat: the drug must be labelled with a boxed warning and prescribed using a medication guide. This decision was made based on the fact that some patients on the drug could experience dangerously low blood sodium levels – a condition known as hyponatremia.


Keywords: Drug Approval, FDA, Boxed Warning


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.